Wikisage, the free encyclopedia of the second generation, is digital heritage
Bezafibrate: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases | Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases | ||
This fibrate reduce triglyceride and riseHDL-cholesterol<ref>[https://www.jstage.jst.go.jp/article/jat/22/7/22_ED007/_pdf How Does Bezafibrate Affect the Plasma HDL Cholesterol Levels?]</ref><gallery> | This fibrate reduce triglyceride and riseHDL-cholesterol<ref>[https://www.jstage.jst.go.jp/article/jat/22/7/22_ED007/_pdf How Does Bezafibrate Affect the Plasma HDL Cholesterol Levels?]</ref><ref>[https://www.jstage.jst.go.jp/article/jat/22/7/22_27425/_pdf Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes.]</ref> | ||
<gallery> | |||
File:4528-62340-1-PB.jpg | File:4528-62340-1-PB.jpg | ||
</gallery> | </gallery> | ||
Revision as of 00:36, 5 November 2015
Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases This fibrate reduce triglyceride and riseHDL-cholesterol[1][2]
ursodeoxycholic acid and bezafibrate are under study in the treatment of biliar cyrrhosis (See Figure)
- ↑ How Does Bezafibrate Affect the Plasma HDL Cholesterol Levels?
- ↑ Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes.
- ↑ Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis
- ↑ Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis